Dr. Wiland, Et Al, Reply.

To the Editor: We thank Prof. Bannwarth for his insight into the potential influence of methotrexate (MTX) dosing in the PRIZE clinical trial1. The objective of the PRIZE study was to compare sustained remission rates after 39 weeks of reduced medication in patients with rheumatoid arthritis who had first achieved remission after 52 weeks’ treatment with a combination of etanercept (ETN), 50 mg subcutaneously (SC) once a week, and MTX, orally 10–25 mg once a … Address correspondence to Prof. P. Wiland, Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Borowska 213, 50-556 Wroclaw, Poland. E-mail: pwiland1{at}gmail.com